HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Sulfadiazine

HCID 5215
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
68-35-9
Standard SMILES
Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1
InChIKey
SEEPANYCNGTZFQ-UHFFFAOYSA-N
Molecular formula
C10H10N4O2S
Average molar mass
250.28 g/mol
Monoisotopic mass
250.05244675

Overview

Sulfadiazine is a sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position. It has a role as an antimicrobial agent, an antiinfective agent, a xenobiotic, a coccidiostat, an antiprotozoal drug, an EC 2.5.1.15 (dihydropteroate synthase) inhibitor, an EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor, an environmental contaminant and a drug allergen. It is a sulfonamide, a member of pyrimidines, a substituted aniline and a sulfonamide antibiotic. It is functionally related to a sulfanilamide. It is a conjugate acid of a sulfadiazinate.

Names & identifiers

Preferred name
Sulfadiazine
IUPAC
4-amino-N-pyrimidin-2-ylbenzenesulfonamide
English name
Sulfadiazine
Molecular formula
C10H10N4O2S
Molecular weight
250.28

Names & synonyms

sulfadiazine68-35-9SulphadiazineSulfapyrimidineSulfadiazinAdiazineCoco-Diazine2-SulfanilamidopyrimidineSulfolexBenzenesulfonamide, 4-amino-N-2-pyrimidinyl-2-Sulfanilylaminopyrimidine4-amino-N-pyrimidin-2-ylbenzenesulfonamide
Show more names
Sulfadiazine,(S)SulfadiazeneDiazinSulfoseTerfonylDiazoloneNeotrizinesuldadiazine
4-amino-N-(pyrimidin-2-yl)benzene-1-sulfonamideN(1)-2-pyrimidylsulfanilamideN(sup 1)-2-PyrimidinylsulfanilamideN(1)-2-pyrimidinylsulfanilamide4-AMINO-N-2-PYRIMIDINYLBENZENESULFONAMIDEDTXSID7044130CHEBI:9328NSC35600

Database identifiers

CAS
68-35-9
PubChem CID
5215
DTXSID
DTXSID7044130
ChEMBL
CHEMBL439
ChEBI
CHEBI:9328
UNII
0N7609K889

Properties

Computed structural properties

XLogP
-0.1
Topological polar surface area
106 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
6
Rotatable bonds
3
Heavy atoms
17
Formal charge
0
Complexity
327

Experimental & physicochemical properties

Drugs · 4 items

Pharmaceuticals -> Antibiotics

Pharmaceuticals

Pharmaceuticals -> Antibiotics (Sulfonamide)

Pharmaceuticals -> Listed in ZINC15

SpringerMaterials PropertiesFusion temperature
LogP · 2 items

-0.2

-0.04

Solubility6.01e-01 g/L
Human Drugs · 3 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Anti-infective medicines

Animal Drugs · 3 items

FDA approved animal drugs -> Active ingredient

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Pharmaceuticals -> UK Veterinary Medicines Directorate List

Physical DescriptionSolid
Dissociation Constants6.36

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 1.2% (2 of 171) of reports.

Danger

H302 (98.2%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P233, P260, P261, P263, P264, P264+P265, P270, P271, P272, P273, P280, P284, P301+P317, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P330, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P391, P403, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 171 reports by companies from 21 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

REACH registered substance: Sulfadiazine (EC: 200-685-8)

Sulphadiazine: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (98.2%)

Toxicology

Hepatotoxicity · 1 item

Sulfadiazine, like other sulfonamides, causes a characteristic idiosyncratic liver injury which has features of drug-allergy or hypersensitivity. The typical onset is sudden development of fever and rash followed by jaundice within a few days or weeks of starting the medication. The pattern of injury is typically mixed, although fatal cases are often hepatocellular and prolonged cholestatic cases have also been described. Eosinophilia or atypical lymphocytosis are also common and the clinical pattern can be considered a part of DRESS syndrome (drug rash with eosinophilia and systemic symptoms). Cases of Stevens Johnson syndrome due to sulfadiazine have also been described. Sulfonamides such as sulfadiazine have been linked to many cases of acute liver failure and as a class, the sulfonamides still rank in the top 5 to 10 causes of drug induced, idiosyncratic fulminant hepatic failure. However, most cases of sulfonamide induced liver injury resolve rapidly, usually within 2 to 4 weeks unless cholestasis is severe. Onset of injury is more rapid with rechallenge and can appear within a day or reexposure. Patients with hepatic injury due to sulfadiazine may have a history of previous exposure to the drug without injury. Sulfonamides such as sulfadiazine can also cause mild and transient ALT elevations that do not progress to jaundice or more severe liver injury either alone or as a part of a generalized hypersensitivity reaction. Sulfonamides have also been linked to hepatic granulomas.

Chemistry & industry

Pharmacology

ATC Code · 4 items

J01EC02

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

J01EC02

Pharmacodynamics · 1 item

Sulfadiazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of <i>p</i>-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.

Mechanism of Action · 1 item

Sulfadiazine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.

Metabolism/MetabolitesSulfadiazine has known human metabolites that include Sulfadiazine hydroxylamine.
FDA Pharmacological Classification · 6 items

0N7609K889

SULFADIAZINE

Established Pharmacologic Class [EPC] - Sulfonamide Antibacterial

Chemical Structure [CS] - Sulfonamides

Sulfadiazine is a Sulfonamide Antibacterial.

SULFADIAZINE

MeSH Pharmacological Classification · 3 items

Related reactions

36 records
New reaction record
HRID 3696 reaction equation
HRID 3696As reactant
HRID 94566 reaction equation
HRID 94566As reactant
HRID 156477 reaction equation
HRID 156477As reactant
HRID 213337 reaction equation
HRID 213337As reactant
HRID 365062 reaction equation
HRID 365062As product
HRID 489948 reaction equation
HRID 489948As reactant
HRID 583483 reaction equation
HRID 583483As reactant
HRID 697622 reaction equation
HRID 697622As reactant
PreviousPage 1 of 5

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
EC Number
200-685-8
Nikkaji
J1.418D
Collision Cross Section · 5 items

153.9 Ų [M+H]+ [CCS Type: TW; Method: calibrated with Waters Major Mix]

150.9 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

148.7 Ų [M+H]+ [CCS Type: TW]

150.09 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

151.96 Ų [M+H]+

Physicochemical properties

Melting point
253 °C · 253 °C (dec.) (lit.)
Boiling point
512.6 · 512.6±52.0 °C(Predicted)
Density
1.378 · 1.3780 (rough estimate)
refractive index
1.644 · 1.6440 (estimate)
storage temp.
2 · 2-8°C
solubility
Soluble in dimethyl sulfoxide.
pka
2.21 · pKa 2.21(H2O t = 25 I = 0.5 (NaCl)) (Uncertain)
form
powder
color
white
Water Solubility
67.13 mg/L · 67.13mg/L(25 ºC)
Merck
14 · 14,8903
BRN
6733588 · 6733588
BCS Class
4 · 4/3
Major Application
clinical testing
InChI
1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
InChIKey
SEEPANYCNGTZFQ-UHFFFAOYSA-N
SMILES
Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2
CAS DataBase Reference
68 · 68-35-9(CAS DataBase Reference)
EWG's Food Scores
1 · 1
FDA UNII
0 N7609K889 · 0N7609K889
ATC code
1 EC02 · J01EC02
NIST Chemistry Reference
Sulfadiazine(68-35-9)
EPA Substance Registry System
4 · Benzenesulfonamide, 4-amino-N-2-pyrimidinyl- (68-35-9)
UNSPSC Code
51283908 · 51283908
NACRES
85 · NA.85
Protein binding
20 · 20-55%
Excreted unchanged in urine
80 % · 80%
Volume of distribution
0.29 · 0.29(L/kg)
Biological half-life
17 · 17 / Prolonged
Symbol(GHS)
7 · GHS07,GHS08,GHS09
Signal word
Warning
Hazard statements
302 · H302-H361d-H362-H411
Precautionary statements
202 · P202-P260-P263-P273-P301+P312-P308+P313
PPE
95 · dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Hazard Codes
Xn,Xi
Risk Statements
22 · 22-36/37/38-42/43-43-42
Safety Statements
26 · 26-36
RIDADR
3249 · 3249
WGK Germany
3 · 3
RTECS
1925000 · WP1925000
F
10 · 10
TSCA
TSCA listed
HazardClass
6.1 · 6.1(b)
PackingGroup
III
HS Code
29335990 · 29335990
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
4 OralAquatic · Acute Tox. 4 OralAquatic Chronic 2Repr. 2
Toxicity
50 oral · LD50 oral in mouse: 1500mg/kg
REACH Registrations
Active
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Sulfadiazine

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

EPA Human Health Benchmarks for Pharmaceuticals · 6 items

Sulfadiazine

46.6

197.2

The initial usual adult dosage is 2 g to 4 g. The maintenance dosage is 2 g to 4 g, divided into 3 to 6 doses, every 24 hours.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 2000 mg/day, Lowest Therapeutic Dose (LTD): 25.0 mg/kg-day, and Screening Dose: 0.008 mg/kg-day.

30-Jun-20

Safety data

F
10
PPE
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
wgk
3
tsca
TSCA listed
rtecs
WP1925000
ridadr
3249
hs_code
29335990
Toxicity
LD50 oral in mouse: 1500mg/kg
risk_code
22-36/37/38-42/43-43-42
Signal word
Warning
Symbol(GHS)
GHS07,GHS08,GHS09
hazard_code
Xn,Xi
safety_code
26-36
hazard_class
6.1(b)
Storage Class
11 - Combustible Solids
packing_group
III
Hazard statements
H302-H361d-H362-H411
REACH Registrations
Active
Hazard Classifications
Acute Tox. 4 OralAquatic Chronic 2Repr. 2
Precautionary statements
P202-P260-P263-P273-P301+P312-P308+P313

Substances that are destructive to protozoans.

Agents useful in the treatment or prevention of COCCIDIOSIS in man or animals.

Substances that inhibit the growth or reproduction of BACTERIA.

Absorption, Distribution and ExcretionSulfadiazine is excreted largely in the urine.
Cellular LocationsMembrane

Uses & manufacturing

UsesUse (kg) in Switzerland (2009): >250
Use Classification · 2 items

Pharmaceuticals -> Antiinfectives for systemic use -> Antibacterials for systemic use -> Sulfonamides and trimethoprims -> Intermediate-acting sulfonamides -> Antibiotics

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

General Manufacturing InformationBenzenesulfonamide, 4-amino-N-2-pyrimidinyl-: ACTIVE
Applications · 5 items

UsesIt is excellent kinds of sulfa drugs with strong antibacterial activity, good efficacy, rapid absorption, slow excretion rate and high plasma concentration. It is clinically used for treating upper respiratory tract infection, Meningococcal meningitis, otitis media, boils carbuncle, puerperal fever, urinary tract infections and acute dysentery and so on. It is a sulfa-type drug which is used for the treatment of infection caused by hemolytic streptococcus, pneumococcus, meningococcis, Neisseria gonorrhea, and E. coli. It is a sulfa drug with antibacterial effect and convergence effect.

UsesIt is used in the form of silver salts (sulfadiazine silver) as an external antibacterial agent, primarily for treating burns. It is believed that the presence of the silver ion in the molecule facilitates increased antimicrobial and wound-healing action.

UsesSulfonamide antibacterial.

UsesDMSO soluble potent immunosuppressant, neuroprotective neuroregenerative, in vitro T cell proliferation blocker. disrupts calcineurin-mediated signal transduction in T lymphocytes

General DescriptionSulfadiazine’s plasma half-life is 17 hours. It is a white,odorless crystalline powder soluble in water to the extentof 1:8,100 at 37°C and 1:13,000 at 25°C, in human serumto the extent of 1:620 at 37°C, and sparingly soluble in alcoholand acetone. It is readily soluble in dilute mineralacids and bases. Its pKa is 6.3.

Upstream & downstream products

Upstream raw materials

Thiamine chlorideEthyl vinyl etherEthanolN,N-DimethylformamidePropargyl alcoholDiethylamineCalcium carbideSodium MethoxidePhosphorus trichlorideSulfaguanidine4-Nitrobenzenesulfonyl chloride2-Aminopyrimidine

Downstream products

2-Chloro-N-{4-[(pyrimidin-2-ylamino)sulfonyl]phenyl}acetamide2-chloro-5-nitro-N-[4-(pyrimidin-2-ylsulfamoyl)phenyl]benzamide

Additional notes

DefinitionChEBI: A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.